Anti-transcriptional intermediary factor 1- γ antibody-positive dermatomyositis induced by nivolumab for lung adenocarcinoma: A case report

In conclusion, our case demonstrates that the development of dermatomyositis was causally related to immune activation by nivolumab. Given the potential exacerbation of autoimmune paraneoplastic disorders in cancer patients receiving immunotherapy, clinicians should be aware of early manifestations of systemic irAEs that require prompt diagnosis and intervention.
Source: Investigational New Drugs - Category: Drugs & Pharmacology Source Type: research